A direct comparative study of methylation-specific PCR in ductal lavage fluid, breast cancer tissue, normal breast parenchyma and plasma in women with early breast cancer by Gui, GPH et al.
BioMed  Central
Page 1 of 2
(page number not for citation purposes)
BMC Proceedings
Open Access Meeting abstract
A direct comparative study of methylation-specific PCR in ductal 
lavage fluid, breast cancer tissue, normal breast parenchyma and 
plasma in women with early breast cancer
GPH Gui*1, D Twelves1,3, A Nerurkar2, P Osin2, A Ward1, T Crook3 and 
CM Isacke3
Address: 1Academic Surgery (Breast Unit), Institute of Cancer Research, London, UK, 2Department of Histopathology, Royal Marsden NHS Trust, 
Institute of Cancer Research, London, UK and 3Breakthrough Breast Cancer, Institute of Cancer Research, London, UK
Email: GPH Gui* - gerald.gui@rmh.nhs.uk
* Corresponding author    
Introduction
Breast duct lavage for analysis by methylation-specific
PCR is a novel but established method for detecting the
presence of cancer and may contribute additional infor-
mation about prognosis and response to treatment. The
aim of this consecutive series of breast cancer patients was
a case-control study to evaluate qualitative methylation of
five published tumour suppressor genes1 in breast cancer
tissue, adjacent normal breast parenchyma, duct lavage
fluid and plasma.
Methods
Breast cancer tissue and adjacent normal parenchymal tis-
sue was obtained at the time of surgery in 24 women. Nor-
mal breast tissue from 22 patients undergoing breast
surgery without breast cancer were used as controls. In all
patients, tissue cores, matched plasma, ipsilateral and
contralateral duct lavage fluid were obtained for methyla-
tion-specific PCR. DNA was purified from microdissected
tissue, plasma and breast duct biofluids using the QUIA-
GEN DNeasy kit. Purified DNA was then modified (EZ
Zymo methylation kit) for detection of methylated
regions in five genes: HIN-1, RIL, RASSF1A, CDH13 and
RAR2, by optimised specific-PCR. Proportional data
with binomial errors were used to compare cancer vs con-
trol samples.
Results
Methylated DNA products were qualitatively scored and a
positive correlation identified between tumour tissue and
ipsilateral duct lavage in the breast cancer group (n = 24):
HIN-1 (58 and 50%), RIL (63 and 42%), RASSF1A (71
and 54%), CDH13 (42 and 33%) and RAR2 (38 and
25%. Methylation was significantly higher in tumour and
ipsilateral duct lavage fluid when compared with adjacent
normal tissue and contralateral duct lavage. (See Table 1.)
Methylation was less when scored as accumulated meth-
ylation events in benign breast tissue and duct lavage of
22 non-cancer patients: HIN (4% and 4%), RIL (8% and
0%), RASSF1A (13 and 0%), CDH13 (13 and 4%), RAR2
(0%). No difference was found in plasma methylation of
cancer patients versus controls. (a1-sided = 5%; power =
90%)
Conclusion
Our data demonstrates the feasibility to modify purified
DNA from cellular breast duct fluid for detection of meth-
ylated products by methylation-specific PCR, with a sig-
nificant difference in rates of DNA methylation in duct
lavage of cancer patients versus controls. These differences
were unrelated to plasma methylation profiles, limiting
blood testing as a biomarker of breast cancer progression.
The inclusion of other tumour suppressor genes in future
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studies may increase the sensitivity and specificity of
breast-specific biofluids in subclinical cancer.
Table 1: 
CANCER (n = 24) CONTROLS (n = 22)
Tumour tissue Normal tissue Ipsilat DL Contra DL Plasma Normal tissue Ipsilat DL Plasma
HIN-1 14 5 12 0 0 1 1 0
RIL 15 4 10 1 2 2 0 1
RASSF1A 17 7 13 0 0 3 0 0
C D H 1 3 1 0 5 82 0 3 10
RAR29 4 6 0 1 0 0 0
Ipsilat = Ipsilateral; Contra = Contralateral; DL = ductal lavage.